In vivo targeted reprogramming of CAR T cells could be achieved through CD3‐targeting nanoparticles.[276] CD8 T cell‐targeted nanoparticles encapsulating immunostimulatory agents demonstrate higher efficacy in tumor growth control and prolonging survival.[277] Notably, targeting functional markers, such as PD‐1, can also be achieved.[277] These discoveries have the potential to be applied in targeting specific responders of immunotherapies, calling for future research endeavors. The gene discussed is CD8A; the disease is neoplasm.